Onco-Bio

Daewoong Pharmaceutical is a research-driven Korean pharmaceutical company dedicated to improving patient outcomes in immune-mediated diseases. Its rheumatology portfolio includes Xelenka® (adalimumab biosimilar) and Xeltofa® (tofacitinib generic), providing high-quality, accessible treatment options that support sustainable healthcare and broaden patient access across Asia.